180 related articles for article (PubMed ID: 12762762)
1. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
2. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
4. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazolone p38 inhibitors.
Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
[TBL] [Abstract][Full Text] [Related]
7. Synthetic methodology utilized to prepare substituted imidazole p38 MAP kinase inhibitors.
Murry JA
Curr Opin Drug Discov Devel; 2003 Nov; 6(6):945-65. PubMed ID: 14758763
[TBL] [Abstract][Full Text] [Related]
8. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
Koch P; Jahns H; Schattel V; Goettert M; Laufer S
J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles.
Pierre Koch ; Christiane Bäuerlein ; Hartmut Jank ; Stefan Laufer
J Med Chem; 2008 Sep; 51(18):5630-40. PubMed ID: 18763757
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
12. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
13. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
O'Shea PD; Chen CY; Chen W; Dagneau P; Frey LF; Grabowski EJ; Marcantonio KM; Reamer RA; Tan L; Tillyer RD; Roy A; Wang X; Zhao D
J Org Chem; 2005 Apr; 70(8):3021-30. PubMed ID: 15822960
[TBL] [Abstract][Full Text] [Related]
14. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Bamford MJ; Bailey N; Davies S; Dean DK; Francis L; Panchal TA; Parr CA; Sehmi S; Steadman JG; Takle AK; Townsend JT; Wilson DM
Bioorg Med Chem Lett; 2005 Jul; 15(14):3407-11. PubMed ID: 15955699
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
16. Ones, thiones, and N-oxides: an exercise in imidazole chemistry.
Laufer S; Wagner G; Kotschenreuther D
Angew Chem Int Ed Engl; 2002 Jul; 41(13):2290-3. PubMed ID: 12203569
[No Abstract] [Full Text] [Related]
17. A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.
Selig R; Goettert M; Schattel V; Schollmeyer D; Albrecht W; Laufer S
J Med Chem; 2012 Oct; 55(19):8429-39. PubMed ID: 22951114
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
19. Substituted isoxazoles as potent inhibitors of p38 MAP kinase.
Laufer SA; Margutti S; Fritz MD
ChemMedChem; 2006 Feb; 1(2):197-207. PubMed ID: 16892352
[TBL] [Abstract][Full Text] [Related]
20. IRAK-4 inhibitors. Part 1: a series of amides.
Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
